Etude : CARLHA /



ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.


Acronyme
Nom
Traitement
Dernière MÀJ
Présentation de l'étude
Acronyme : CARLHA

Nom :

Traitement :

Dernière MÀJ : 25/09/2017
Titre
Spécialité(s)
CIM10 - Localisation(s)
Informations principales
Titre : Évaluation de la toxicité et de l'efficacité de la radiothérapie combinée à 6 mois de traitement hormonal agoniste LH-RH et abiratérone dans les rechutes biologiques de cancer de la prostate après chirurgie

Spécialité : Organes génitaux masculins
Localisation : C61 - Tumeur maligne de la prostate
Schéma
Phase
Stade
Ligne(s)
Informations complémentaires
Schéma : Etude non randomisée, en ouvert, avec un seul bras de traitement: HORMONO + ACETATE ABIRATERONE + PREDNISONE + RADIOTHERAPIE

Phase : I/II

Stade : NA

NA
Critères d'inclusion
Critères de non-inclusion
Critères d'inclusion et de non-inclusion
Critères d'inclusion : - Histologically confirmed prostate adenocarcinoma
- The patients should have undergone only surgery for localized prostate adenocarcinoma: pT2, pT3 or pT4 with bladder neck involvement
- pN0: negative lymphadenectomy at the time of prostatectomy
- At inclusion the patients should have no clinical signs of progressive disease and should be M0 (bone and pelvic scans).
- ≥ 18 years of age with life expectancy ≥ 10 years
- Performance Status (ECOG) ≤ 1
- PSA ≤ 0.1 ng/ml after prostatectomy (dosage performed within 2 months after surgery)
- PSA ≥ 0.2 ng/ml et ≤ 2 ng/ml at the time of inclusion
- Elevation of PSA over three consecutive assays performed in the same laboratory, with a minimal interval of two months between assays, (PSA nadir level followed by two other progressive assays)
- At least 6 months between surgery and biochemical relapse
- Serum potassium ≥ 3.5 mmol/L in the 72 hours before first dose of abiraterone acetate
- Serum creatinine < 1.5 x ULN or a calculated creatinine clearance ≥ 60 mL/min
- Liver function: Serum bilirubin < 1.5 x ULN (except for patients with documented Gilbert's disease) AST and ALT < 2.5 x ULN
- Patients must be affiliated to a Social Security System.
- Patient information and written informed consent form signed for both principal and additional research
- Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures

Critères de non-inclusion : - pN1: histologically-proven lymph node involvement at initial lymphadenectomy
- Histology other than adenocarcinoma
- Previous hormone therapy including prior therapy with ketoconazole or other CYP17 inhibitor(s) for prostate cancer.
- Patients being treated within the last 14 days prior to inclusion with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A4 (Clarithromycin, Ketoconazole, Itraconazole, Voriconazole, Ritanovir, see appendix 11) or requiring those treatments during the study
- Active or symptomatic viral hepatitis or chronic liver disease
- Surgical or chemical castration
- History of cancer, with the exception of basal cell carcinoma or any other cancer treated in the 5 years before inclusion and in complete remission.
- Previous pelvic radiotherapy
- Uncontrolled hypertension (defined as systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg). Patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy (see appendix 10 for mandatory BP measurement guidelines)
- Severe and moderate hepatic impairment (Child-Pugh class B and C)
- Patients with severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to: Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
- Known hypersensitivity to any of the study drugs or excipients.
- Galactosemia, Glucose-galactose malabsorption or lactase deficiency
- Patients with any psychological, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- Individual deprived of liberty or placed under the authority of a tutor.
- Patients already included in another therapeutic trial with an experimental drug or having been given an experimental drug within a period of 30 days.
NCT
Promoteur
Contact ARC
Coordonnateur
Informations relatives au promoteur
NCT :
Promoteur :
UNICANCER
Type de sponsor : Institutionnel
44800 ST HERBLAIN

Contact ARC :

Coordonnateur :
Stéphane SUPIOT
stephane.supiot@ico.unicancer.fr
0240679933
Centre investigateur
Investigateur
TEC / ARC / IDE
État
Type d'étude
MÀJ
Informations relatives aux investigateurs
Centre investigateur :
Centre François BACLESSE - 3 avenue du Général Harris - 14000 CAEN

Investigateur :
Florence JOLY

TEC / ARC / IDE :
Jérémy BOUTROIS
j.boutrois@
baclesse.unicancer.fr

Ouverture de l'essai : CLOS

Type d'étude : Hors ciblage moléculaire / Hors innovation thérapeutique
MAJ : 03/12/2018